Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ViRx
All patients take ABT-378/ritonavir and efavirenz; there are no placebos in this study. Patients take study medications for 48 weeks, during which time there will be 15 study visits. There is a possibility of a study extension after 48 weeks.
Age
0–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients may be eligible for this study if they:
Are HIV-positive.
Have a viral load (level of HIV in the blood) of at least 1,000 copies/ml.
Have been receiving stable (no changes) anti-HIV treatment that includes at least 1 PI for at least 8 weeks prior to study entry.
Have received more than 1 PI for at least 12 weeks each at some time in the past.
You may not be if
Patients will not be eligible for this study if they:
Have had any active opportunistic (AIDS-related) infections within the past 30 days.
Have ever received nonnucleoside reverse transcriptase inhibitors (NNRTIs), such as delavirdine, nevirapine, or efavirenz.
Have received certain medications.
Are pregnant or breast-feeding.
Abuse alcohol or drugs.
Clareo Health | ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past
